Cardiovascular
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.
Bayer Cuts Dividend To The Bone To Cut Debt
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
IsomAb Nabs Decent Seed Funding Despite Tricky Funding Climate
The University of Nottingham spin-out has raised £7.5m for a candidate that could halt the progression of peripheral arterial disease in diabetics.
Alnylam Surprises Investors With Last-Minute HELIOS-B Revisions
Alnylam pushed back the study’s top-line readout to June or July. But analysts said the changes increase the odds of demonstrating monotherapy benefit with Amvuttra in ATTR-CM.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
CSL’s High Hopes For Heart Attack Therapy Come Crashing Down
The Australian firm has reported disappointing results from an 18,200-patient trial of its plasma-derived apolipoprotein A-I therapy which did not cut the risk of major adverse cardiovascular events following acute myocardial infarction.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.